Monoclonal Antibodies Market in Rheumatoid Arthritis to 2018 - Market Characterized by Large and Diversified Pipeline and Low Threat of Biosimilar Sales Erosion

Publisher Name :
Date: 31-Jan-2013
No. of pages: 134

GBI Research, the leading business intelligence provider, has released its latest research, "Monoclonal Antibodies Market in Rheumatoid Arthritis to 2018 Market Characterized by Large and Diversified Pipeline and Low Threat of Biosimilar Sales Erosion". The currently marketed monoclonal antibodies are clinically and commercially highly successful products in the rheumatoid arthritis market, constituting four of the global top 20 best-selling drugs. The unique density of monoclonal antibodies that are approved for this indication, significant market exclusivity expiries in the forecast period and yet more monoclonal antibodies in development will change the dynamics in and this highly lucrative market in the forecast period until 2018.

Scope


  • The current therapeutic environment in the treatment of RA across the top seven developed markets, including the US, Germany, France, the UK, Italy, Spain and Japan.

  • Analysis of the competitive environment for monoclonal antibodies with strong data and evidence-based profiling of marketed products, including comparative benchmarking and assessment of efficacy and safety profiles as well as differentiating product features.

  • A detailed pipeline analysis for monoclonal antibodies in rheumatoid arthritis including individual product profiles, a comparative efficacy and safety profile heat map analysis of the most promising pipeline products as well as analyses on the distribution of molecule types across the RA developmental pipeline, the molecular targets of pipeline mAbs and the developmental program types. In addition, detailed analyses of the clinical trial failure rates, the clinical trial durations by phase and clinical trial sizes by participant numbers are provided.

  • Market data on the geographical landscape and therapeutic landscape, including market size, annual cost of therapy, treatment usage patterns such as disease population and prescription populations.

  • Market forecasts across the US, the top five countries in Europe (EU5) Germany, France, the UK, Italy, and Spainas well as Japan. The multiple scenario forecasts take a range of factors that are likely to vary into account and provide a clear perspective on the level of the potential degree of variance in the market sizes.


Key market drivers and barriers

The major deals that have taken place in the monoclonal antibodies market in rheumatoid arthritis in recent years. Coverage includes Mergers and Acquisitions (M&As) as well as co-development and licensing agreements, which are segmented on the basis of geography and total value. A concomitant analysis of the licensing deal values for products by molecule types and molecular targets is also provided.

Reasons To Buy


  • Understand the competitive environment for monoclonal antibodies

  • Develop key strategic repositioning initiatives by studying the repositioning trends and strategies of current competitors

  • Understand the clinical and commercial impact of the growing diversification of the molecular targets of monoclonal antibodies in the pipeline and identify potential first-in-class products

  • Assess the potential clinical and commercial impact of current late-stage pipeline molecules on the RA market in the forecast period

  • Use the clinical trial failure rate analysis to assess the risk profiles of current and/or future developmental programs for monoclonal antibodies in RA

  • Use key benchmark data to forecast costs of developmental programs for monoclonal antibodies in RA by using proprietary clinical trial size and duration analyses

  • Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps

  • Use proprietary data analyses to assess the market value of pipeline molecules for in-licensing and out-licensing opportunities

Monoclonal Antibodies Market in Rheumatoid Arthritis to 2018 - Market Characterized by Large and Diversified Pipeline and Low Threat of Biosimilar Sales Erosion

Table Of Contents

1 Table of Contents 6
1.1 List of Tables 9
1.2 List of Figures 10

2 Introduction 12
2.1 Symptoms 12
2.2 Etiology 13
2.3 Pathophysiology 13
2.3.1 Disease Initiation 13
2.3.2 Disease Propagation 14
2.4 Co-Morbidities and Complications 15
2.5 Diagnosis 16
2.5.1 Physical Examination 16
2.5.2 Blood Tests 16
2.5.3 X-Ray Imaging 17
2.6 Classification 17
2.7 Epidemiology 19
2.8 Prognosis and Disease Staging 19
2.9 Measurement of Treatment Effectiveness 20
2.10 Treatment Options 21
2.10.1 Pharmacological 21
2.10.2 Treatment Algorithms and Prescribing Habits 25
2.10.3 Non-Pharmacological Care 28

3 Marketed Products 29
3.1 Therapeutic Landscape 30
3.1.1 Remicade (infliximab) - Johnson and Johnson, Merck 30
3.1.2 Humira (adalimumab) - Abbott Laboratories 32
3.1.3 Enbrel (etanercept) - Amgen Inc., Pfizer Inc. and Takeda Pharmaceutical Co. Ltd. 34
3.1.4 Rituxan (rituximab) - Genentech (Roche Group), Biogen IDEC Inc. 36
3.1.5 Orencia (abatacept) - Bristol-Myers Squibb 38
3.1.6 Actemra (tocilizumab) -F Hoffman La Roche Ltd. 40
3.1.7 Simponi (golimumab) - Johnson and Johnson, Merck 42
3.1.8 Cimzia (certolizumab pegol) - UCB S.A. 43
3.1.9 Remsima (biosimilar infliximab) - Celltrion Inc. 44
3.2 Comparative Efficacy and Safety 44
3.3 Unmet Need 47

4 Pipeline for Rheumatoid Arthritis Monoclonal Antibody Therapeutics 48
4.1 Overall Pipeline 48
4.2 Molecular Targets in the Pipeline 49
4.3 Clinical Trials 52
4.3.1 Failure Rate 52
4.3.2 Patient Enrolment and Clinical Trial Size 56
4.3.3 Duration 59
4.4 Promising Drug Candidates in the Pipeline 61
4.4.1 Arzerra (ofatumumab) - Genmab A/S, GlaxoSmithKline Plc. 61
4.4.2 LY2127399 (tabalumab) - Eli Lily and Company 61
4.4.3 REGN88 (sarilumab) - Regeneron Pharmaceuticals Inc. 62
4.4.4 CNTO 136 (sirukumab) - Johnson and Johnson 62
4.4.5 AIN457 (secukinumab) - Novartis 63
4.4.6 ALD-518 - Alder Biopharmaceuticals Inc. 63
4.4.7 BT-061 (tregalizumab) - Biotest A.G. 63
4.4.8 MLTA3698A (pateclizumab) - Genentech Inc. 64
4.4.9 MOR 103 - MorphoSys A.G. 64
4.5 Heat Map of Safety and Efficacy for Pipeline and Marketed Products 65
4.6 Conclusion 66

5 Market Forecast to 2018 68
5.1 Geographical Markets 68
5.1.1 Global Market 69
5.1.2 US 71
5.1.3 UK 73
5.1.4 France 75
5.1.5 Germany 77
5.1.6 Italy 79
5.1.7 Spain 81
5.1.8 Japan 83
5.2 Drivers and Barriers for the mAbs market in Rheumatoid Arthritis 85
5.2.1 Drivers 85
5.2.2 Barriers 87

6 Deals and Strategic Consolidations 90
6.1 Mergers and Acquisition Deals 91
6.1.1 Amgen Completes Acquisition of Micromet, Inc. 91
6.1.2 Pfizer Inc. Completes Acquisition of Wyeth 92
6.1.3 Bristol-Myers Squibb Completes Acquisition of Medarex Inc. 92
6.1.4 Teva Pharmaceutical Industries Limited Acquires CoGenesys Inc. 92
6.1.5 Biotie Therapies Corp. Terminates Acquisition of Newron Pharmaceuticals S.p.A. 92
6.1.6 Emergent BioSolutions Inc. Completes Acquisition of Trubion Pharmaceuticals Inc. 92
6.1.7 Alexion Pharmaceuticals Inc. completes acquisition of Taligen Therapeutics Inc. 93
6.1.8 Ligand Pharmaceuticals Incorporated Completes Acquisition of Pharmacopeia Inc. 93
6.1.9 Astellas Pharma Inc. Completes Acquisition of Perseid Therapeutics LLC 93
6.1.10 Cypress Bioscience Inc. Completes Acquisition of Proprius Pharmaceuticals Inc. 93
6.1.11 Simcere Pharmaceutical Group Completes Acquisition of Shanghai Celgen Bio-Pharmaceutical Co. Ltd. 93
6.2 Major Co-development Deals 94
6.2.1 Abbott Laboratories Enters Worldwide Agreement with Biotest AG 94
6.2.2 Dynavax Technologies Corporation Expands Worldwide Agreement with GlaxoSmithKline plc 95
6.2.3 Astellas Pharma Inc. Enters into Agreement with Maxygen Inc. 95
6.2.4 Tanabe Research Laboratories Enters Agreement with Anaphore Inc. 95
6.3 Major Licensing Deals 96
6.3.1 Hanwha Chemical Corporation Enter Licensing Agreement with Merck Sharp and Dohme Research Ltd. 99
6.3.2 Alder Biopharmaceuticals Inc. Enter Agreement with Bristol-Myers Squibb Company 99
6.3.3 Immunomedics Inc. Enter Agreement with Nycomed International Management GmbH 99
6.3.4 Sanofi-Aventis Enter Agreement with Kyowa Hakko Kogyo Co. Ltd. 99
6.3.5 EUSA Pharma Inc. Enter Licensing Agreement with GlaxoSmithKline plc 100

7 Appendix 101
7.1 All Pipeline Drugs by Phase 101
7.1.1 Discovery 101
7.1.2 Preclinical 102
7.1.3 IND-Filed and Phase 0 106
7.1.4 Phase I 106
7.1.5 Phase II 108
7.1.6 Phase III 110
7.1.7 Undisclosed 111
7.2 Market Forecasts to 2018 112
7.2.1 Global 112
7.2.2 United States 113
7.2.3 Top Five European Countries (Aggregate) 114
7.2.4 UK 115
7.2.5 France 116
7.2.6 Germany 117
7.2.7 Italy 118
7.2.8 Spain 119
7.2.9 Japan 120
7.3 Market Definitions 121
7.4 Abbreviations 121
7.5 References for Heat Maps (Figure 12 and Figure 23) 123
7.6 Sources 125
7.7 Research Methodology 130
7.7.1 Coverage 130
7.7.2 Secondary Research 130
7.7.3 Primary Research 131
7.7.4 Therapeutic Landscape 131
7.7.5 Geographical Landscape 134
7.7.6 Pipeline Analysis 134
7.8 Expert Panel Validation 134
7.9 Contact Us 134
7.10 Disclaimer 134

1.1 List Of Tables

Table 1: American College of Rheumatology Classification Guidelines for Rheumatoid Arthritis, 2010-2012 18
Table 2: Monoclonal Antibodies Market in Rheumatoid Arthritis, Global, Pharmaceutical Pipeline (Discovery), 2012 101
Table 3: Monoclonal Antibodies Market in Rheumatoid Arthritis, Global, Pharmaceutical Pipeline (Preclinical), 2012 102
Table 4: Monoclonal Antibodies Market in Rheumatoid Arthritis, Global, Pharmaceutical Pipeline (IND-Filed and Phase 0), 2012 106
Table 5: Monoclonal Antibodies Market in Rheumatoid Arthritis, Global, Pharmaceutical Pipeline (Phase I), 2012 106
Table 6: Monoclonal Antibodies Market in Rheumatoid Arthritis, Global, Pharmaceutical Pipeline (Phase II), 2012 108
Table 7: Monoclonal Antibodies Market in Rheumatoid Arthritis, Global, Pharmaceutical Pipeline (Phase III), 2012 110
Table 8: Monoclonal Antibodies Market in Rheumatoid Arthritis, Global, Pharmaceutical Pipeline (Filed), 2007-2012 110
Table 9: Monoclonal Antibodies Market in Rheumatoid Arthritis, Global, Pharmaceutical Pipeline (Undisclosed Developmental Phase), 2012 111
Table 10: Monoclonal Antibodies Market for Rheumatoid Arthritis, Global, Market Forecast, 2004-2018 112
Table 11: Monoclonal Antibodies Market for Rheumatoid Arthritis, Global, Market Forecast, 2004-2018 112
Table 12: Monoclonal Antibodies Market for Rheumatoid Arthritis, US, Market Forecast, 2004-2018 113
Table 13: Monoclonal Antibodies Market for Rheumatoid Arthritis, Top Five European Countries, Market Forecast, 2004-2018 114
Table 14: Monoclonal Antibodies Market for Rheumatoid Arthritis, UK, Market Forecast, 2004-2018 115
Table 15: Monoclonal Antibodies Market for Rheumatoid Arthritis, France, Market Forecast, 2004-2018 116
Table 16: Monoclonal Antibodies Market for Rheumatoid Arthritis, Germany, Market Forecast, 2004-2018 117
Table 17: Monoclonal Antibodies Market for Rheumatoid Arthritis, Italy, Market Forecast, 2004-2018 118
Table 18: Monoclonal Antibodies Market for Rheumatoid Arthritis, Spain, Market Forecast, 2004-2018 119
Table 19: Monoclonal Antibodies Market for Rheumatoid Arthritis, Japan, Market Forecast, 2004-2018 120
Table 20: Monoclonal Antibodies Market for Rheumatoid Arthritis, Heat Maps for Efficacy and Safety of Marketed and Pipeline Products, References 123

1.2 List Of Figures

Figure 1: American College of Rheumatology Treatment Guidelines, Early Rheumatoid Arthritis, 2012 26
Figure 2: American College of Rheumatology Treatment Guidelines, Established Rheumatoid Arthritis, 2012 27
Figure 3: Monoclonal Antibodies Market in Rheumatoid Arthritis, Global, Annual Sales ($m), 2011 29
Figure 4: Remicade (infliximab), Global, Annual Sales ($m), 2003-2011 31
Figure 5: Humira (adalimumab), Global, Annual Sales ($m), 2003-2011 32
Figure 6: Enbrel (etanercept), Global, Annual Sales ($m), 2003-2011 34
Figure 7: Rituxan (rituximab), Global, Annual Sales ($m), 2002-2011 36
Figure 8: Orencia (abatacept), Global, Annual Sales ($m), 2006-2011 38
Figure 9: Actemra (tocilizumab), Global, Annual Sales ($m), 2008-2011 40
Figure 10: Simponi (golimumab), Global, Annual Sales ($m), 2009-2011 42
Figure 11: Cimzia (certolizumab pegol), Global, Annual Sales ($m), 2008-2011 43
Figure 12: Monoclonal Antibodies Market in Rheumatoid Arthritis, Global, Comparative Safety and Efficacy of Marketed Products (Heat Map), 2012 45
Figure 13: Rheumatoid Arthritis Market, Global, Pipeline, 2012 48
Figure 14: Monoclonal Antibodies Market in Rheumatoid Arthritis, Global, Pipeline by Molecular Target, 2012 49
Figure 15: Monoclonal Antibodies Market in Rheumatoid Arthritis, Global, Novel Pipeline by Molecular Target, 2012 50
Figure 16: Monoclonal Antibodies Market in Rheumatoid Arthritis, Global, Clinical Trial Failure Rates (%), 1999-2012 53
Figure 17: Monoclonal Antibodies Market in Rheumatoid Arthritis, Global, Proportion of Inferred Clinical Trial Failure and Success Rates (%), 1999-2012 54
Figure 18: Monoclonal Antibodies Market in Rheumatoid Arthritis, Global, Reasons for Clinical Trial Failure (All Phases) (%), 1999-2012 55
Figure 19: Monoclonal Antibodies Market in Rheumatoid Arthritis, Global, Mean Clinical Trial Sizes (n), 1999-2012 56
Figure 20: Monoclonal Antibodies Market in Rheumatoid Arthritis, Global, Estimated Cumulative Clinical Trial Size (?000), 1999-2012 58
Figure 21: Monoclonal Antibodies Market in Rheumatoid Arthritis, Global, Mean Clinical Trial Duration (Months), 1999-2012 59
Figure 22: Monoclonal Antibodies Market in Rheumatoid Arthritis, Global, Mean Number of Clinical Trials Per Pipeline Drug, With Sample Size (n), 1999-2012 60
Figure 23: Monoclonal Antibodies Market in Rheumatoid Arthritis, Global, Comparative Safety and Efficacy of Marketed and Late-Stage Pipeline Products (Heat Map), 2012 65
Figure 24: Monoclonal Antibodies Market for Rheumatoid Arthritis, Global, Annual Sales ($bn), 2004-2018 70
Figure 25: Rheumatoid Arthritis Therapeutic Monoclonal Antibodies Market, US, Treatment Patterns, 2004-2018 72
Figure 26: Monoclonal Antibodies Market in Rheumatoid Arthritis, UK, Treatment Usage Patterns (?000), 2004-2018 74
Figure 27: Monoclonal Antibodies Market in Rheumatoid Arthritis, France, Treatment Usage Patterns (?000), 2004-2018 76
Figure 28: Monoclonal Antibodies Market in Rheumatoid Arthritis, Germany, Treatment Usage Patterns (?000), 2004-2018 78
Figure 29: Monoclonal Antibodies Market in Rheumatoid Arthritis, Italy, Treatment Usage Patterns (?000), 2004-2018 80
Figure 30: Monoclonal Antibodies Market in Rheumatoid Arthritis, Spain, Treatment Usage Patterns (?000), 2004-2018 82
Figure 31: Rheumatoid Arthritis Therapeutic Monoclonal Antibodies Market, Japan, Treatment Patterns (?000), 2004-2018 84
Figure 32: Monoclonal Antibodies Market in Rheumatoid Arthritis, US, Indications for Marketed RA Antibodies (Chronology of FDA Approvals), 1997-2012 86
Figure 33: Monoclonal Antibodies Market in Rheumatoid Arthritis, Global, Mean Clinical Trial Duration for Novel and Biosimilar Products (Months), with Sample Size (n), 1999-2012 89
Figure 34: Monoclonal Antibodies Market in Rheumatoid Arthritis, Global, Mergers and Acquisition Deals, 2007-2012 90
Figure 35: Monoclonal Antibodies Market in Rheumatoid Arthritis, Global, Mergers and Acquisition Deals, 2007-2012 91
Figure 36: Monoclonal Antibodies Market in Rheumatoid Arthritis, Global, Co-Development Deals, 2004-2012 94
Figure 37: Monoclonal Antibodies Market in Rheumatoid Arthritis, Global, Licensing Deals 2004-2012 96
Figure 38: Monoclonal Antibodies Market in Rheumatoid Arthritis, Global, Licensing Deals, 2004-2012 97
Figure 39: Rheumatoid Arthritis, Global, Licensing Deals (Acquirer Companies), 2004-2012 98
Figure 40: GBI Research Market Forecasting Model 133

  • China Commercial Vehicle Industry
    Commercial vehicle are usually large trucks, buses or vans used to transport people,  goods and material. China is one of the nations that contributes to over 50% of commercial vehicle production. The industry has grown in leaps and bounds over the couple of years. Even though the growth rates aren’t as impressive as two years [...]
  • The Prospective Market of Drug Eluting Stents
    Drug Eluting Stents are the recent development that’s are now being used frequently for curing narrowed coronary arteries. These stents help to keep the artery open and supply drugs at regular intervals preventing any further obstruction. The stents are usually small scaffolds of wire and are placed in the artery. This has been a welcome [...]
  • Anaesthesia Machine Industry is Flourishing due to an Extensive Customer Base with Therapeutic Needs
    The Anaesthesia Machine Industry comprises of the manufacturers and users of Anaesthesia Machines which are basically workstations or units that assist a person to administer Anaesthesia on the other. It includes plug & play Anaesthesia delivery units (ADUs). The industry also comprises of the various accessories like monitors and information systems and support services involved [...]
  • The Need for an Electric Cars Boosts The Lithium Sulfate Market
    Lithium is a highly demanded material. The popularity of this metal is primarily due to the characteristics of this metal and its compounds. Some of the characteristics of this material are that it has the highest electrochemical potential of all metals, a very high co-efficient of thermal expansion, acting as a viscosity modifier in melts, [...]
  • Tire Roller Industry
    Tire roller is one of the most popular equipment used in the construction industry. A tire roller offers multiple services from building highways, industrial sites, binder courses, wear courses and many more. Tire rollers come with different features like easy adjustment of tyres, flexible ballast, oscillating tires, etc. that facilitates in doing a particular work. [...]
    • The Oil Drilling Rig Industry
    • The Oil Drilling Rig Industry is characterized with a few typical work specific to this industry only. The work begins with the search for new oil basins or construction of wells. During this time the services of drilling contractors and se…

    • HER2-Negative Breast Cancer’s Therapeutic Market
    • HER2-Negative Breast Cancer is the most common form of cancer occurring in women. The long term survival of patients diagnosed with HER2-Negative Breast Cancer depends solely on its early detection as till now there is no medicine that can …

    • The Market of Plate Heat Exchanger
    • Plate heat exchanger is not only very useful but its also easy to maintain, its compact design makes it more efficient, the product is highly cost-efficient and also the materials of this product are easily available. There are some limitat…

    • The Industry of Binding Machines
    • Binding of books and papers is one of the most important aspect of buying and selling books and thus the demand of binding machines. There are different kinds of binding machines available in the market. The binding type determines the bind…

    • The Boom In Women Infertility Market
    • Infertility is an abnormality in the regular functioning of the human reproductive system. Anyone of male or female might be suffering from this issue. Infertility in woman is caused by either a genetical factor or factors such as aging or …

  • Global Rheumatoid Arthritis Drugs Market 2011-2015
    Published: 20-Mar-2012        Price: US 1500 Onwards        Pages: 38
    TechNavio's analysts forecast the Global Rheumatoid Arthritis Drugs market to grow at a CAGR of 12.1 percent over the period 2011-2015. One of the key factors contributing to this market growth is the high incidence and prevalence rate of patients suffering from rheumatoid arthritis. The Global Rheumatoid Arthritis Drugs market has also been witnessing the trend of preference for combination therapies for treatment of rheumatoid arthritis. However, patent expiry of blockbuster drugs could pose a......
  • Rheumatoid Arthritis Drugs Market in Japan 2011-2015
    Published: 06-Apr-2012        Price: US 1500 Onwards        Pages: 32
    TechNavio's analysts forecast the Rheumatoid Arthritis market in Japan to grow at a CAGR of 29.2 percent over the period 2011-2015. One of the key factors contributing to this market growth is the high prevalence rate of patients suffering from rheumatoid arthritis. The Rheumatoid Arthritis Drugs market in Japan has also been witnessing a trend of increasing number of collaborations among vendors. However, stringent regulatory requirements for approval of drugs in Japan could pose a challenge to......
  • Rheumatoid Arthritis - Pipeline Review, H2 2012
    Published: 31-Aug-2012        Price: US 2500 Onwards        Pages: 366
    Global Markets Direct’s, ''Rheumatoid Arthritis - Pipeline Review, H2 2012'', provides an overview of the Rheumatoid Arthritis therapeutic pipeline. This report provides information on the therapeutic development for Rheumatoid Arthritis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Rheumatoid Arthritis. ''Rheumatoid Arthritis - Pipeline Review, H2 2012'' is built using data and......
  • Gouty Arthritis (Gout) - Pipeline Review, H2 2012
    Published: 31-Aug-2012        Price: US 2000 Onwards        Pages: 107
    Global Markets Direct’s, ''Gouty Arthritis (Gout) - Pipeline Review, H2 2012'', provides an overview of the Gouty Arthritis (Gout) therapeutic pipeline. This report provides information on the therapeutic development for Gouty Arthritis (Gout), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Gouty Arthritis (Gout). ''Gouty Arthritis (Gout) - Pipeline Review, H2 2012'' is built usin......
  • PharmaPoint: Rheumatoid Arthritis - United States Drug Forecast and Market Analysis Event-Driven Update
    Published: 30-Nov-2012        Price: US 4995 Onwards        Pages: 138
    PharmaPoint: Rheumatoid Arthritis - United States Drug Forecast and Market Analysis Event-Driven Update Summary GlobalData has released its new Country report, "PharmaPoint: Rheumatoid Arthritis - United States Drug Forecast and Market Analysis Event-Driven Update". The RA market is currently very dynamic, with the November 6, 2012 FDA approval of Pfizer's Xeljanz (tofacitinib) and novel oral therapies awaiting approval such as: Eli Lilly's anti-BAFF, tabalumab and JAK1,2 inhibitor, barici......
  • Enbrel (Rheumatoid Arthritis) Forecast and Market Analysis
    Published: 30-Nov-2012        Price: US 3495 Onwards        Pages: 39
    Enbrel (Rheumatoid Arthritis) Forecast and Market Analysis Summary GlobalData has released its new PharmaPoint Drug Evaluation report, Enbrel (Rheumatoid Arthritis) Forecast and Market Analysis. The RA market is currently very dynamic, with the November 6, 2012 FDA approval of Pfizer's Xeljanz (tofacitinib) and novel oral therapies awaiting approval such as: Eli Lilly's anti-BAFF, tabalumab and JAK1,2 inhibitor, baricitinib, and Rigel/AZ's SYK inhibitor, fostamatinib. These compounds will ......
  • PharmaPoint: Rheumatoid Arthritis - United Kingdom Drug Forecast and Market Analysis Event-Driven Update
    Published: 30-Nov-2012        Price: US 4995 Onwards        Pages: 135
    PharmaPoint: Rheumatoid Arthritis - United Kingdom Drug Forecast and Market Analysis Event-Driven Update Summary GlobalData has released its new Country report, "PharmaPoint: Rheumatoid Arthritis - United Kingdom Drug Forecast and Market Analysis Event-Driven Update". The RA market is currently very dynamic, with the November 6, 2012 FDA approval of Pfizer's Xeljanz (tofacitinib) and novel oral therapies awaiting approval such as: Eli Lilly's anti-BAFF, tabalumab and JAK1,2 inhibitor, bari......
  • Humira (Rheumatoid Arthritis) Forecast and Market Analysis
    Published: 30-Nov-2012        Price: US 3495 Onwards        Pages: 36
    Humira (Rheumatoid Arthritis) Forecast and Market Analysis Summary GlobalData has released its new PharmaPoint Drug Evaluation report, Humira (Rheumatoid Arthritis) Forecast and Market Analysis. The RA market is currently very dynamic, with the November 6, 2012 FDA approval of Pfizer's Xeljanz (tofacitinib) and novel oral therapies awaiting approval such as: Eli Lilly's anti-BAFF, tabalumab and JAK1,2 inhibitor, baricitinib, and Rigel/AZ's SYK inhibitor, fostamatinib. These compounds will ......
  • PharmaPoint: Rheumatoid Arthritis - France Drug Forecast and Market Analysis Event-Driven Update
    Published: 30-Nov-2012        Price: US 4995 Onwards        Pages: 135
    PharmaPoint: Rheumatoid Arthritis - France Drug Forecast and Market Analysis Event-Driven Update Summary GlobalData has released its new Country report, "PharmaPoint: Rheumatoid Arthritis - France Drug Forecast and Market Analysis Event-Driven Update". The RA market is currently very dynamic, with the November 6, 2012 FDA approval of Pfizer's Xeljanz (tofacitinib) and novel oral therapies awaiting approval such as: Eli Lilly's anti-BAFF, tabalumab and JAK1,2 inhibitor, baricitinib, and Rig......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs